Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 3
2006 5
2007 5
2008 4
2009 8
2010 2
2011 3
2012 3
2013 3
2014 4
2015 3
2016 6
2017 4
2018 8
2019 8
2020 4
2021 4
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Results by year
Filters applied: . Clear all
Page 1
Repurposed Drugs Trials for Ovarian Cancer.
DiFeo A. DiFeo A. Cancer J. 2019 Mar/Apr;25(2):149-152. doi: 10.1097/PPO.0000000000000366. Cancer J. 2019. PMID: 30896539 No abstract available.
Cisplatin induces stemness in ovarian cancer.
Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, Hitomi M, Nagaraj AB, DiFeo A, Lathia JD, Reizes O. Wiechert A, et al. Among authors: difeo a. Oncotarget. 2016 May 24;7(21):30511-22. doi: 10.18632/oncotarget.8852. Oncotarget. 2016. PMID: 27105520 Free PMC article.
Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.
Achreja A, Yu T, Mittal A, Choppara S, Animasahun O, Nenwani M, Wuchu F, Meurs N, Mohan A, Jeon JH, Sarangi I, Jayaraman A, Owen S, Kulkarni R, Cusato M, Weinberg F, Kweon HK, Subramanian C, Wicha MS, Merajver SD, Nagrath S, Cho KR, DiFeo A, Lu X, Nagrath D. Achreja A, et al. Among authors: difeo a. Nat Metab. 2022 Sep;4(9):1119-1137. doi: 10.1038/s42255-022-00636-3. Epub 2022 Sep 21. Nat Metab. 2022. PMID: 36131208
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G. O'Connor CM, et al. Among authors: difeo a. Oncogene. 2020 Jan;39(3):703-717. doi: 10.1038/s41388-019-1012-2. Epub 2019 Sep 20. Oncogene. 2020. PMID: 31541192 Free PMC article.
71 results